Crizotinib

• IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised
  2023-506686-66-00 Phase II/III 1 country Ideaya Biosciences Inc.
• Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending
  2025-522431-34-00 Phase II 1 country Region Hovedstaden
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting
  2023-505604-32-00 Phase III 10 countries Bristol-Myers Squibb Services Unlimited Company
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 Phase II/III 7 countries Ideaya Biosciences Inc.
• Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe… Recruiting
  2024-516607-16-00 Phase II 1 country Medical University Of Warsaw
• Master Protocol for Crizotinib Continuation Sub-Studies Recruiting
  2024-511128-15-00 Phase IV 1 country Pfizer Inc.
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting
  2023-504880-18-00 Phase I/II 9 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended
  2023-507494-18-00 Phase III 10 countries F. Hoffmann-La Roche AG
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended
  2024-513947-94-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Ended
  2024-513454-29-00 Phase III 7 countries Xcovery Holding Co. LLC
• A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended
  2024-519070-39-00 Phase II 1 country Region Hovedstaden
• A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended
  2023-506859-13-00 Phase III 4 countries F. Hoffmann-La Roche AG

Showing 1–14 of 14 trials